HRP941022B1 - Process for the preparation of leukotriene antagonists - Google Patents

Process for the preparation of leukotriene antagonists

Info

Publication number
HRP941022B1
HRP941022B1 HR08/350,428A HRP941022A HRP941022B1 HR P941022 B1 HRP941022 B1 HR P941022B1 HR P941022 A HRP941022 A HR P941022A HR P941022 B1 HRP941022 B1 HR P941022B1
Authority
HR
Croatia
Prior art keywords
preparation
compound
formula
leukotriene antagonists
het
Prior art date
Application number
HR08/350,428A
Other languages
English (en)
Inventor
James J Bergan
Original Assignee
James J. Bergan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26870681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP941022(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by James J. Bergan filed Critical James J. Bergan
Publication of HRP941022A2 publication Critical patent/HRP941022A2/hr
Publication of HRP941022B1 publication Critical patent/HRP941022B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/53—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
HR08/350,428A 1993-12-28 1994-12-28 Process for the preparation of leukotriene antagonists HRP941022B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17493193A 1993-12-28 1993-12-28
US35042894A 1994-12-09 1994-12-09

Publications (2)

Publication Number Publication Date
HRP941022A2 HRP941022A2 (en) 1997-06-30
HRP941022B1 true HRP941022B1 (en) 1999-12-31

Family

ID=26870681

Family Applications (1)

Application Number Title Priority Date Filing Date
HR08/350,428A HRP941022B1 (en) 1993-12-28 1994-12-28 Process for the preparation of leukotriene antagonists

Country Status (29)

Country Link
US (2) US5614632A (pt)
EP (1) EP0737186B1 (pt)
JP (1) JP3640962B2 (pt)
KR (1) KR100319336B1 (pt)
CN (3) CN101081834B (pt)
AT (1) ATE169906T1 (pt)
AU (1) AU686303B2 (pt)
BG (1) BG62850B1 (pt)
BR (1) BR9408452A (pt)
CA (1) CA2179407C (pt)
CY (1) CY2104B1 (pt)
CZ (1) CZ286079B6 (pt)
DE (1) DE69412644T2 (pt)
DK (1) DK0737186T3 (pt)
ES (1) ES2122534T3 (pt)
FI (1) FI113045B (pt)
GE (1) GEP20012387B (pt)
HK (1) HK1009269A1 (pt)
HR (1) HRP941022B1 (pt)
HU (1) HU226394B1 (pt)
LV (1) LV12313B (pt)
NZ (1) NZ278263A (pt)
PL (1) PL178671B1 (pt)
RO (1) RO119018B1 (pt)
RU (2) RU2140909C1 (pt)
TW (2) TW416948B (pt)
UA (1) UA44724C2 (pt)
WO (1) WO1995018107A1 (pt)
YU (1) YU49412B (pt)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US20030216571A1 (en) * 1999-12-28 2003-11-20 Yoshiaki Kuroki Tricyclic compounds
WO2003066582A1 (en) * 2002-02-06 2003-08-14 Delmar Chemicals Inc. Process for the preparation of 1-(mercaptomethyl)-cyclopropaneacetic acid
WO2003066598A1 (en) * 2002-02-07 2003-08-14 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
AU2004229507B2 (en) * 2003-04-15 2008-12-18 Merck Frosst Canada & Co. Polymorphic form of montelukast sodium
EP1619190B1 (en) * 2003-04-25 2010-12-29 Nippon Chemiphar Co., Ltd. Salts of (2s,3s)-3- [[(1s)-1-isobutoxymethyl-3-methylbutyl]carbamoyl] oxirane-2-carboxylic acid
PT1631550E (pt) * 2003-06-06 2012-04-19 Morepen Lab Ltd Um método melhorado para a preparação do ácido montelucaste e do seu sal de sódio na forma amorfa
IL174758A (en) 2003-10-10 2012-09-24 Synthon Bv Crystalline form of montelukast, pharmaceutical composition comprising it, process for the preparation thereof and uses thereof as a medicament
EP1760077A1 (en) * 2004-01-30 2007-03-07 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
WO2005075427A2 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
WO2005074935A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
JP2007520546A (ja) 2004-02-03 2007-07-26 ケマジス リミティド モンテルカストナトリウムの安定な非晶質性形態
US7189853B2 (en) * 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
JP2007532686A (ja) * 2004-04-21 2007-11-15 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストナトリウムを調製する方法
US7829716B2 (en) 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
EP1812393B1 (en) * 2004-07-19 2011-12-28 Matrix Laboratories Ltd Methyl 2-[(3s)-[3-[(2e)-(7-chloroquinolin-2-yl) ethenyl]phenyl]-3-halopropyl]-benzoate ester
ATE500225T1 (de) * 2004-07-19 2011-03-15 Matrix Lab Ltd Verfahren zur herstellung von montelukast und salzen davon
WO2006021974A1 (en) * 2004-08-23 2006-03-02 Morepen Laboratories Limited A process for synthesizing diol (viii)-an intermediate of montelukast sodium
PL205637B1 (pl) * 2004-10-22 2010-05-31 Inst Farmaceutyczny Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
EP1831171A4 (en) * 2004-11-19 2010-09-15 Matrix Lab Ltd PROCESS FOR THE PREPARATION OF NEW MONTELUKAST SODIUM AMORPHOUS
EP1817289A1 (en) * 2004-11-30 2007-08-15 Medichem, S.A. New process for the preparation of a leukotriene antagonist
ITMI20050247A1 (it) * 2005-02-18 2006-08-19 Chemi Spa Processo per la preparazione di montelukast
CN101213177A (zh) 2005-07-05 2008-07-02 特瓦制药工业有限公司 孟鲁司特的纯化
KR20080033425A (ko) * 2005-07-20 2008-04-16 닥터 레디스 래보러토리즈, 인코포레이티드 몬테루캐스트의 제조 공정
EP1783117A1 (en) * 2005-11-04 2007-05-09 Esteve Quimica, S.A. Process for the preparation of a leukotriene antagonist and intermediates thereof
WO2007059325A2 (en) * 2005-11-16 2007-05-24 Teva Pharmaceutical Industries Ltd. Drying methods of montelukast sodium by azeotropic removal of the solvent
AR056815A1 (es) 2005-11-18 2007-10-24 Synthon Bv PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST
EP1968943B1 (en) * 2005-12-13 2013-01-23 MSN Laboratories Limited An improved process for the preparation of montelukast and its pharmaceutically acceptable salts
EP1968942A4 (en) * 2005-12-23 2010-06-02 Glade Organics Private Ltd IMPROVED PROCESS FOR THE PREPARATION OF SODIUM MONTELUKAST
SI1976522T2 (sl) 2005-12-30 2019-11-29 Krka Tovarna Zdravil D D Novo Mesto Farmacevtski sestavek, ki vsebuje montelukast
WO2007088545A2 (en) * 2006-02-02 2007-08-09 Chemagis Ltd. Novel process for preparing 1-(mercaptomethyl) cyclopropaneacetic acid, a useful intermediate in the preparation of montelukast and salts thereof
SI1818057T1 (sl) * 2006-02-09 2010-08-31 Teva Pharma Stabilne farmacevtske formulacije montelukast natrija
JP2009529495A (ja) * 2006-02-21 2009-08-20 ケマジス・リミテッド モンテルカストアンモニウム塩の新規な多形体およびその調製方法
IL181607A0 (en) * 2006-02-27 2007-07-04 Chemagis Ltd Novel process for preparing montelukast and salts thereof
CN101432267A (zh) 2006-03-17 2009-05-13 斯索恩有限公司 孟鲁司特金刚烷胺盐
US20090281323A1 (en) * 2006-04-12 2009-11-12 Glade Organics Private Limited Process for the manufacture of montelukast sodium
US20090326232A1 (en) * 2006-06-26 2009-12-31 Uttam Kumar Ray Process for the Preparation of Leukotriene Receptor Antagonist (Montelukast Sodium)
GB0614485D0 (en) * 2006-07-21 2006-09-27 Pliva Istrazivanje I Razvoj D Process
WO2008015703A2 (en) * 2006-08-04 2008-02-07 Matrix Laboratories Ltd Process for the preparation of montelukast and its salts thereof
EP1886998A1 (en) * 2006-08-09 2008-02-13 Esteve Quimica, S.A. Purification process of montelukast and its amine salts
NZ575552A (en) * 2006-09-15 2012-02-24 Cipla Ltd Process for the preparation of montelukast, and intermediates therefor
GB0618703D0 (en) * 2006-09-22 2006-11-01 Almac Sciences Ltd Synthesis of leikotriene compounds
US7700776B2 (en) 2006-10-24 2010-04-20 Formosa Laboratories, Inc. Compounds and preparation for montelukast sodium
EP2094665A4 (en) * 2006-11-06 2010-11-24 Reddys Lab Ltd Dr PREPARATION OF MONTELUKAST AND ITS SALTS
WO2008062478A2 (en) * 2006-11-20 2008-05-29 Manne Satyanarayana Reddy Improved process for pure montelukast sodium through pure intermediates as well as novel amine salts
KR100774088B1 (ko) * 2006-12-14 2007-11-06 한미약품 주식회사 몬테루카스트의 제조방법 및 이에 사용되는 중간체
US7271268B1 (en) 2006-12-22 2007-09-18 Formosa Laboratories Inc. Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives
US20080188664A1 (en) * 2007-01-15 2008-08-07 Chemagis Ltd. Process for preparing montelukast sodium containing controlled levels of impurities
EP1958936A1 (en) * 2007-02-14 2008-08-20 Inke, S.A. Process for obtaining montelukast
WO2008126075A1 (en) * 2007-04-12 2008-10-23 Chemagis Ltd. Process for preparing montelukast and salts thereof using optically impure 2-(2-(3(s)-(3-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxypropyl)phenyl-2-propanol
WO2008135966A1 (en) * 2007-05-02 2008-11-13 Chemagis Ltd. Process for the purification of optically impure 2-(2-(3(s)-(3-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxy-propyl)phenyl-2-propanol
PL205444B1 (pl) * 2007-05-02 2010-04-30 Zak & Lstrok Ady Farmaceutyczn Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
CZ302518B6 (cs) * 2007-07-09 2011-06-29 Zentiva, A. S. Zpusob izolace a cištení montelukastu
EP2014633A1 (en) * 2007-07-13 2009-01-14 Lonza Ag Process for the production of tertiary alcohols
ES2320077B1 (es) 2007-07-31 2010-02-26 Moehs Iberica, S.L. Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo.
WO2009027990A1 (en) * 2007-08-29 2009-03-05 Morepen Laboratories Limited Salts of montelukast and process therefor
KR101072896B1 (ko) 2007-10-09 2011-10-17 한미홀딩스 주식회사 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
US20100305080A1 (en) * 2007-10-25 2010-12-02 O'shea Paul Novel Crystalline Salts of Montelukast
EP2053043A1 (en) 2007-10-26 2009-04-29 Inke, S.A. Crystalline salt of montelukast
DE102007061630B4 (de) 2007-12-20 2013-07-04 Formosa Laboratories, Inc. Neue Verbindungen und Herstellung von Montelukast-Natrium
US20100292251A1 (en) * 2008-01-07 2010-11-18 Torrent Pharmaceuticals Limited Montelukast benzhydryl piperazine salts and process for preparation thereof
CN101817818B (zh) * 2008-03-06 2011-10-26 台耀化学股份有限公司 一种用于制备孟鲁司特钠的化合物
CN101323589B (zh) * 2008-03-06 2010-10-06 台耀化学股份有限公司 化合物及孟鲁司特钠的制备方法
EP2265586A4 (en) * 2008-03-17 2012-10-03 Reddys Lab Ltd Dr PREPARATION OF MONTELUKAST AND ITS SALTS
WO2009130056A1 (en) * 2008-04-25 2009-10-29 Synthon B.V. Process for making montelukast intermediates
CA2723398C (en) * 2008-05-05 2017-07-04 Abbott Gmbh & Co. Kg Method for evaluating the solubility of a crystalline substance in a polymer
EP2288595B1 (en) * 2008-05-26 2016-11-02 Laurus Labs Private Limited An improved process for preparing montelukast and salts thereof
KR101123292B1 (ko) * 2008-09-26 2012-03-19 주식회사 엘지생명과학 몬테루카스트 나트륨염의 제조방법
WO2010064109A2 (en) 2008-12-02 2010-06-10 Mayuka Labs Private Limited An improved process for the preparation of montelukast sodium and its intermediates
WO2010148209A2 (en) * 2009-06-19 2010-12-23 Dr. Reddy's Laboratories Ltd. Preparation of montelukast
WO2011004298A1 (en) 2009-07-09 2011-01-13 Alembic Limited Montelukast hexamethylenediamine salt and its use for the preparation of montelukast sodium
EP2287154A1 (en) * 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast
CN101638381B (zh) 2009-09-02 2012-08-29 鲁南制药集团股份有限公司 孟鲁司特钠中间体的合成方法
WO2011033470A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Crystalline form of montelukast sodium
CN102574803A (zh) * 2009-10-09 2012-07-11 帝斯曼知识产权资产管理有限公司 用于制备孟鲁司特的光学活性中间体的合成
AU2009357276A1 (en) 2009-12-23 2012-08-09 Pharmathen S.A. Improved process for the preparation of Montelukast and salts thereof
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
HUP1000425A2 (en) 2010-08-11 2012-03-28 Richter Gedeon Nyrt Process for the production of montelukast sodium
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
EP2502910A1 (en) 2011-03-15 2012-09-26 Laboratorios Lesvi, S.L. Camphorsulfonic salt of a key Montelukast intermediate
CN102633683B (zh) * 2012-04-06 2014-05-21 盐城市晶华化工有限公司 一种1-羟甲基环丙基乙腈合成方法
WO2014001860A1 (en) * 2012-05-18 2014-01-03 Laurus Labs Private Limited Process for preparation of montelukast sodium
CN103539714A (zh) * 2012-07-16 2014-01-29 上海朴颐化学科技有限公司 1-巯甲基环丙基乙酸及其中间体的制备方法
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
WO2014081616A1 (en) * 2012-11-21 2014-05-30 Merck Sharp & Dohme Corp. Preparation of precursors for leukotriene antagonists
WO2014118796A1 (en) 2013-01-31 2014-08-07 Melody Healthcare Pvt. Ltd. An in-situ process for the preparation of highly pure montelukast sodium
CN103570618A (zh) * 2013-09-30 2014-02-12 浙江车头制药股份有限公司 一种孟鲁司特钠盐的制备方法
CA2936332A1 (en) 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
CN104119270A (zh) * 2014-08-12 2014-10-29 牡丹江恒远药业有限公司 一种孟鲁司特钠的制备方法
CN105085391B (zh) * 2015-06-10 2017-08-22 广东默泰同创医药科技有限公司 用作白三烯受体拮抗剂的环丙基不饱和喹啉化合物及应用
CN105541786B (zh) * 2016-01-06 2017-08-08 鲁南贝特制药有限公司 一种孟鲁司特钠侧链中间体及其制备方法
CN109503476A (zh) * 2018-12-26 2019-03-22 哈尔滨珍宝制药有限公司 一种孟鲁司特钠的合成工艺
CN111170939A (zh) * 2019-12-20 2020-05-19 牡丹江恒远药业股份有限公司 一种高纯度孟鲁司特钠及其中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256675A (en) * 1989-08-07 1993-10-26 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same
FR2665159B1 (fr) * 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5428033A (en) * 1990-10-12 1995-06-27 Merck Frosst Canada, Inc. Saturated hydroxyalkylquinoline acids as leukotriene antagonists
ES2114882T3 (es) * 1990-10-12 1998-06-16 Merck Frosst Canada Inc Acidos hidroxialquilquinolinos insaturados como antagonistas de leucotrienos.
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5358946A (en) * 1992-05-29 1994-10-25 The Du Pont Merck Pharmaceutical Company Heterocycle-substituted amides, carbamates and ureas as agents for the treatment of atherosclerosis
US5270234A (en) * 1992-10-30 1993-12-14 International Business Machines Corporation Deep submicron transistor fabrication method
CA2111372C (en) * 1992-12-22 2007-01-16 Robert N. Young Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists
US5371096A (en) * 1993-08-27 1994-12-06 Ciba-Geigy Corporation (3-pyridyl)tetrafuran-2-yl substituted carboxylic acids

Also Published As

Publication number Publication date
FI113045B (fi) 2004-02-27
HU226394B1 (en) 2008-11-28
HK1009269A1 (en) 1999-05-28
HUT76279A (en) 1997-07-28
LV12313A (lv) 1999-07-20
DK0737186T3 (da) 1999-02-08
ES2122534T3 (es) 1998-12-16
LV12313B (en) 1999-11-20
US6320052B1 (en) 2001-11-20
PL178671B1 (pl) 2000-05-31
JP3640962B2 (ja) 2005-04-20
BG100638A (bg) 1997-03-31
AU686303B2 (en) 1998-02-05
CA2179407A1 (en) 1995-07-06
HRP941022A2 (en) 1997-06-30
PL315155A1 (en) 1996-10-14
RU2225398C2 (ru) 2004-03-10
CN1326837C (zh) 2007-07-18
CZ187896A3 (en) 1996-12-11
HU9601775D0 (en) 1996-09-30
CN101081834A (zh) 2007-12-05
JPH09507235A (ja) 1997-07-22
CN1046712C (zh) 1999-11-24
EP0737186B1 (en) 1998-08-19
US5614632A (en) 1997-03-25
FI962641A0 (fi) 1996-06-26
CY2104B1 (en) 2002-04-05
RO119018B1 (ro) 2004-02-27
YU49412B (sh) 2006-01-16
CZ286079B6 (cs) 2000-01-12
ATE169906T1 (de) 1998-09-15
AU1444895A (en) 1995-07-17
RU2140909C1 (ru) 1999-11-10
YU77594A (sh) 1997-09-30
DE69412644T2 (de) 1999-02-11
FI962641A (fi) 1996-06-26
WO1995018107A1 (en) 1995-07-06
EP0737186A1 (en) 1996-10-16
CN101081834B (zh) 2011-08-24
CN1219535A (zh) 1999-06-16
KR100319336B1 (ko) 2002-04-22
DE69412644D1 (de) 1998-09-24
UA44724C2 (uk) 2002-03-15
TW416948B (en) 2001-01-01
BG62850B1 (bg) 2000-09-29
NZ278263A (en) 1998-04-27
CA2179407C (en) 2009-03-17
GEP20012387B (en) 2001-03-25
BR9408452A (pt) 1997-08-05
TW448160B (en) 2001-08-01
CN1139429A (zh) 1997-01-01

Similar Documents

Publication Publication Date Title
HK1009269A1 (en) Process for the preparation of leukotriene antagonists
DE3479119D1 (en) Novel carbostyril derivative and process for preparing same
AU2719888A (en) Quinoline derivatives as antagonists of leukotriene d4
AU591640B2 (en) Quinolonecarboxylic acid derivatives
AU5567486A (en) Improved process for quinoline-3-carboxylic acid antibacterial agents
AU587885B2 (en) Improved process for quinoline-3-carboxylic acid antibacterial agents
ES8506652A1 (es) Un metodo de preparar dihidrobenzopirrolbenzodiazepinas
ES8606283A1 (es) Procedimiento para preparar derivados de acidos quinolon- carboxilicos
EP0331078A3 (en) Process for the preparation of optically active 4-oxo-1-benzopyran-2-carboxylic acid derivatives and intermediates thereof
PT80791A (fr) Procede de preparation de nouvelles phenyl-naphtiridines utiles notamment comme medicaments anti-ulceres
JPS57203067A (en) Novel quinolinecarboxylic acid derivatives, their preparations, and antibacterial agent comprising them as active ingredient
AU630839B2 (en) Sulfinyl imidazole derivatives and antiulcer agents containing the same
ES8706115A1 (es) Procedimiento para preparar un derivado de pirrolidina
ES2006917A6 (es) Un procedimiento para la preparacion del acido 1-etil-6-fluor-4-oxo-7-morfolin-1,4-dihidro-3-quinolincarboxilico.
JPS6416746A (en) Anisole derivative and production thereof
JPS57154167A (en) Pharmaceutical composition having diuretic, hypotensive and antihydropic activity

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

PNAN Change of the applicant name, address/residence

Owner name: SCHERING CORPORATION, US

Owner name: MERCK SHARP & DOHME CORP., US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20131217

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20141228